MATINAS BIOPHARMA HOLDINGS, INC. Finance Lease, Right-of-Use Asset, Accumulated Amortization
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Finance Lease, Right-of-Use Asset, Accumulated Amortization of $22.90 thousand as of 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization · last filed 2020-05-11
- 2020-03-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $22.90K.
- 2019-03-31: Finance Lease, Right-of-Use Asset, Accumulated Amortization $36.40K.
| Period end | Finance Lease, Right-of-Use Asset, Accumulated Amortization |
|---|---|
| 2020-03-31 | $22.90K 10-Q · filed 2020-05-11 |
| 2019-03-31 | $36.40K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |